New Israeli Treatment Offers Hope For Cancer Patients

By Abigail Klein Leichman, Israel21c November 27, 2012 Comments

A seven-year-old girl with aplastic anemia, a 54-year-old woman with lymphoma and a 45-year-old man with acute myeloid leukemia all walked out the doors of Jerusalem’s Hadassah Medical Center in the past several months after receiving an experimental treatment with an Israeli placenta-based cell therapy to beef up their bone marrow.

Related articles

The Israeli Health Ministry had approved each of these patients for compassionate use of Pluristem Therapeutics’ Placental eXpanded (PLX) cells because their medical conditions were grave despite conventional treatments. Though the youngest of the three patients died four months after the Pluristem therapy, the startup is still banking on the product’s potential.

“This is a real breakthrough,” said Dr. Reuven Or, Hadassah’s director of bone marrow transplantation and cancer immunology, commenting on the condition of Hana, the lymphoma patient.

“The treatment with PLX cells has saved her life and can certainly be classified as a medical miracle. The result of this unique case demonstrates that PLX cells could potentially be effective for use in cancer patients, who receive bone marrow transplantation following severe radiation and chemotherapy treatments, which severely damage their bone marrow.”

In August, the Haifa-based company applied for orphan drug status for its PLX cells with the US Food and Drug Administration for the treatment of aplastic anemia, a condition in which the marrow decreases, or stops production of blood cells.

To continue reading this article, click here.
Photo by UGA College of Ag

Facebook Comments
Raphael Recanati International School Banner
OurCrowd Global Investor Summit Banner
Load more